Evidence map›Paper›PMID 34292344›Full record

ArticlePsychopharmacology2021

Response to sertraline is associated with reduction in anxiety-potentiated startle in premenstrual dysphoric disorder.

Liisa Hantsoo, Christian Grillon, Mary Sammel, Rachel Johnson, Joanna Marks, C Neill Epperson

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02777372 (Psychophysiology, Neurosteroids, and Stress in Premenstrual Dysphoric Disorder), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02777372 phase4completednot on this map

Psychophysiology, Neurosteroids, and Stress in Premenstrual Dysphoric Disorder

TypeinterventionalSponsorJohns Hopkins UniversityRan2016 to 2021Enrolled84ConditionsPMDD, Stress, MoodArmsSertraline
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Liisa HantsooDepartment of Psychiatry & Behavioral Sciences, The Johns Hopkins University School of Medicine, 550 N. Broadway Street, Baltimore, MD, 21205, USA. LHantso1@jhmi.edu.ORCID http://orcid.org/0000-0002-3402-9499
Christian GrillonNational Institute of Mental Health, 15K North Drive, Bethesda, MD, 20892, USA.
Mary SammelDepartment of Biostatistics and Informatics, Colorado School of Public Health, 13001 E. 17th Place, Mail Stop B119, Aurora, CO, 80045, USA.
Rachel JohnsonDepartment of Biostatistics and Informatics, Colorado School of Public Health, 13001 E. 17th Place, Mail Stop B119, Aurora, CO, 80045, USA.
Joanna MarksCollege of Nursing, Thomas Jefferson University, 130 S. 9th Street, Philadelphia, PA, 19107, USA.
C Neill EppersonDepartment of Psychiatry, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, 80045, USA.
Colorado School of Public Health · USJohns Hopkins University · USNational Institute of Mental Health · USThomas Jefferson University · USUniversity of Colorado Anschutz Medical Campus · US

Funding

The Psychophysiology Of Fear And AnxietyZIAMH002798 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI GRILLON, CHRISTIAN · 2009 to 2022
$29.0M
Psychophysiology, Neurosteroids, and Stress in Premenstrual Dysphoric Disorder (PMDD)K23MH107831 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI HANTSOO, LIISA VICTORIA · 2016 to 2020
$905k
Brain and Behavior Research Foundation Young Investigator AwardNIMH NIH HHS K23 MH107831
6 · The paper itself

Abstract

rationaleWomen with premenstrual dysphoric disorder (PMDD) appear to have altered central nervous system sensitivity to neuroactive steroid hormones, manifesting as affective symptoms and heightened arousal in the luteal phase of the menstrual cycle. In particular, women with PMDD appear less sensitive to allopregnanolone, a positive allosteric GABA-A receptor (GABA-A-R) modulator.

objectivesThis study evaluated psychophysiologic reactivity in women with PMDD in the follicular and luteal phases of the menstrual cycle, utilizing anxiety-potentiated startle (APS), a potential translational marker of GABA-A-R sensitivity. The study also assessed APS response to low-dose sertraline treatment in women with PMDD.

methodsParticipants' APS and fear-potentiated startle (FPS) were assessed in the follicular and luteal phases. Women with PMDD received 50 mg sertraline in the following luteal phase to examine impact on APS and FPS.

resultsThere were no significant differences between controls (n = 41) and PMDD participants (n = 36) in change from follicular to luteal phases in baseline startle, APS nor FPS. However, among participants who responded to sertraline, APS was higher in the untreated luteal phase than the follicular phase, but lower in the treated luteal phase than the follicular phase.

conclusionThese data demonstrate elevated psychophysiologic arousal in the luteal phase among some women with PMDD, suggesting impaired ability to modulate arousal reactivity. Specifically, alterations in APS suggest potential GABA-A-R changes across the menstrual cycle and in response to sertraline among treatment responders.

Indexed as

Premenstrual Dysphoric DisorderPremenstrual SyndromeAnxietyAnxiety DisordersFemaleHumansMenstrual CycleSertralineSertralineAcoustic startle responseDepressionGABAMenstrual cycleNeuroactive steroidPremenstrualProgesterone

Identifiers

PMID34292344
PMCPMC11146287
OpenAlexW3185232192

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.